Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (4) Autor De Souza,C.A. (4) Vigorito,A.C. (3) Eid,K.A.B. (2) Miranda,E.C.M. (2) Oliveira,G.B. (2) Aranha,F.J.P. (1) Aranha,J.F.P. (1) Baldissera,R.C. (1) Benites,B.D. (1) Congiu,A.M. (1) Costa,F.F. (1) Damasio,E. (1) Fattori,A. (1) Hackel,C. (1) Lorand-Metze,I. (1) Marino,G. (1) Nati,S. (1) Saad,S.T.O. (1) Santini,G. (1) Schulz,E. (1) Mais... Palavra-chave High-dose cyclophosphamide (2) APAF-1 (1) Acute myeloid leukemia (1) Allogeneic bone marrow transplantation (1) Amifostine (1) Apoptosis (1) Autologous peripheral blood progenitor cell transplantation (1) Chemotherapy resistance (1) Cytoprotection (1) Malignant lymphomas (1) Non-Hodgkin's lymphoma (1) Peripheral blood progenitor cell mobilization (1) Salvage therapy (1) Selection of donors (1) Social and economic conditions (1) Mais... Tipo do documento Info:eu-repo/semantics/article (4) Ano 2008 (1) 2003 (1) 2002 (1) 2000 (1) País Brazil (4) Idioma Inglês (4)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 4 Primeira ... 1 ... Última The availability of full match sibling donors and feasibility of allogeneic bone marrow transplantation in Brazil BJMBR Eid,K.A.B.; Miranda,E.C.M.; Vigorito,A.C.; Aranha,F.J.P.; Oliveira,G.B.; De Souza,C.A.. The feasibility of allogeneic bone marrow transplantation (alloBMT) in a developing country has not yet been demonstrated. Many adverse factors including social and economic limitations may reduce the overall results of this complex and expensive procedure. Our objective was to characterize the most important clinical, social and economic features of candidates for transplantation and their potential donors as well as the influence of these factors on overall survival in a retrospective and exploratory analysis at a university hospital. From July 1993 to July 2001, candidates for BMT were referred to the Bone Marrow Transplantation Unit by Hematology and Oncology Centers from several regions of Brazil. A total of 1138 patients were referred to us as... Tipo: Info:eu-repo/semantics/article Palavras-chave: Allogeneic bone marrow transplantation; Selection of donors; Social and economic conditions. Ano: 2003 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000300005 Low expression of APAF-1XL in acute myeloid leukemia may be associated with the failure of remission induction therapy BJMBR Benites,B.D.; Fattori,A.; Hackel,C.; Lorand-Metze,I.; De Souza,C.A.; Schulz,E.; Costa,F.F.; Saad,S.T.O.. Apoptotic protease activating factor 1 (APAF-1) has a critical role in the regulation of apoptosis. In the present study, the mRNA expression analysis of different APAF-1 transcripts (APAF-1S, APAF-1LC, APAF-1LN, and APAF-1XL) was analyzed in bone marrow samples from 37 patients with acute myeloid leukemia (newly diagnosed, with no previous treatment). APAF-1XL and APAF-1LN transcripts (with and without an extra WD-40 repeat region, respectively) were detected in all samples, although the major form expressed was APAF-1XL in 65% of the samples (group 1), while 35% of the samples expressed primarily APAF-1LN (group 2). Only 46% of the patients presented complete remission in response to remission induction therapy (represented by less than 5% marrow blasts... Tipo: Info:eu-repo/semantics/article Palavras-chave: APAF-1; Acute myeloid leukemia; Apoptosis; Chemotherapy resistance. Ano: 2008 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000700004 High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma BJMBR Baldissera,R.C.; Aranha,J.F.P.; Oliveira,G.B.; Vigorito,A.C.; Eid,K.A.B.; Miranda,E.C.M.; De Souza,C.A.. Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin's disease (39.4%) were enrolled and treated using high dose... Tipo: Info:eu-repo/semantics/article Palavras-chave: Malignant lymphomas; High-dose cyclophosphamide; Autologous peripheral blood progenitor cell transplantation; Salvage therapy. Ano: 2002 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002000100007 Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study BJMBR De Souza,C.A.; Santini,G.; Marino,G.; Nati,S.; Congiu,A.M.; Vigorito,A.C.; Damasio,E.. Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75.9%) affected by aggressive and 7... Tipo: Info:eu-repo/semantics/article Palavras-chave: Amifostine; Cytoprotection; Non-Hodgkin's lymphoma; High-dose cyclophosphamide; Peripheral blood progenitor cell mobilization. Ano: 2000 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2000000700009 Registros recuperados: 4 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco